News

July 7, 2021

Scorpion Therapeutics Announces New CEO Axel Hoos, M.D., Ph.D.

BOSTON, MA. — July 7, 2021 — Scorpion Therapeutics, Inc., a next-generation oncology company developing best- and first-in-class precision medicines for cancer patients, today announced that...

Boston, MA  |   April 8, 2021

Scorpion Therapeutics Appoints Guy Padbury, Ph.D. as Chief Development Officer

BOSTON — April 8, 2021 — Scorpion Therapeutics, Inc., a next-generation precision oncology company, today announced the appointment of Guy Padbury, Ph.D. as Chief Development Officer....

February 25, 2021

Scorpion Therapeutics Announces Leadership Change

– Board Appoints Adam Friedman, M.D., Ph.D., as Interim CEO –  Scorpion Therapeutics announced that Adam Friedman, M.D., Ph.D., has been appointed Chief Executive Officer on an interim basis. The Board of Directors is currently evaluating...
READ MORE NEWS

IN THE MEDIA

STAT (Subscription Required)   |   July 9, 2021

Scorpion Therapeutics hired Axel Hoos as chief executive officer. Previously, he worked at GlaxoSmithKline, where he was senior vice president of R&D governance chair and therapeutic area...

Boston Business Journal   |   July 9, 2021

Just eight months out of stealth, precision medicine startup Scorpion Therapeutics has netted a big fish in Axel Hoos, the head of oncology at GlaxoSmithKline plc,...

Scrip (Subscription Required)   |   July 7, 2021

Axel Hoos will become the CEO of a Boston-based cancer start-up focusing on targeted precision drugs. He talked to Scrip about the decision to leave GSK after 10...

BioCentury (Subscription Required)   |   July 7, 2021

GSK is losing one of the principal architects of its oncology renaissance as immuno-oncology pioneer Axel Hoos prepares to leave the company for his first CEO...

Fierce Biotech   |   July 7, 2021

After leading oncology teams at GlaxoSmithKline and Bristol Myers Squibb, Axel Hoos, M.D., Ph.D., is heading back to biotech.  

Endpoints   |   July 7, 2021

Axel Hoos has long kept the flame alive at GlaxoSmithKline’s oncology division, enduring lean days after the British pharma ditched its late-stage pipeline to Novartis and...

Fierce Biotech   |   January 12, 2021

Less than three months after breaking cover with an impressive $102 million series A, Scorpion has whipped up another major funding round, nabbing $162 million for its next-gen cancer drugs.

Boston Globe   |   January 12, 2021

Just over two months after announcing its debut with $108 million in funding, Boston startup Scorpion Therapeutics said Thursday it has raised an even larger amount of venture capital.

Endpoints News   |   January 12, 2021

Whatever investors have peeped about Gary Glick and Keith Flaherty’s game plan to bring about Precision Oncology 2.0, it’s good enough for a $162 million infusion into Scorpion Therapeutics just weeks after its $108 million Series A.

Fierce Biotech   |   October 26, 2020

When Gary Glick, Ph.D., left the CEO post at IFM Therapeutics, he didn’t know what was next. But he soon found himself on a plane with Loxo Oncology co-founder Keith Flaherty, and they got to talking about how they could “expand the boundaries of targeted oncology.”

Events

J.P. Morgan 39th Annual Healthcare Conference   |   January 13, 2021

Investor Contact
Hannah Deresiewicz
Stern Investor Relations, Inc.
hannah.deresiewicz@sternir.com
212-362-1200

Media Contact
Ravi Moorthy
ravi@scorpiontx.com